BACKGROUND: Fragile X syndrome (FXS) is a single-gene disorder with a broad spectrum of involvement and a strong association with autism. Altered immune responses have been described in autism and there is potential that in children with FXS and autism, an abnormal immune response may play a role. OBJECTIVES: To delineate specific patterns of cytokine/chemokine profiles in individuals with FXS with and without autism and to compare them with typical developing controls. METHODS: Age matched male subjects were recruited through the M.I.N.D. Institute and included: 19 typically developing controls, 64 subjects with FXS without autism and 40 subjects with FXS and autism. Autism diagnosis was confirmed with ADOS, ADI-R and DSM IV criteria. Plasma was isolated and cytokine and chemokine production was assessed by Luminex multiplex analysis. RESULTS: Preliminary observations indicate significant differences in plasma protein levels of a number of cytokines, including IL-1alpha, and the chemokines; RANTES and IP-10, between the FXS group and the typical developing controls (p<0.01). In addition, significant differences were observed between the FXS group with autism and the FXS without autism for IL-6, eotaxin, MCP-1 (p<0.04). CONCLUSIONS: In this study, the first of its kind, we report a significantly altered cytokine profile in FXS. The characterization of an immunological profile in FXS with and without autism may help to elucidate if an abnormal immune response may play a role and help to identify mechanisms important in the etiology of autism both with and without FXS. Copyright 2010. Published by Elsevier Inc.
BACKGROUND:Fragile X syndrome (FXS) is a single-gene disorder with a broad spectrum of involvement and a strong association with autism. Altered immune responses have been described in autism and there is potential that in children with FXS and autism, an abnormal immune response may play a role. OBJECTIVES: To delineate specific patterns of cytokine/chemokine profiles in individuals with FXS with and without autism and to compare them with typical developing controls. METHODS: Age matched male subjects were recruited through the M.I.N.D. Institute and included: 19 typically developing controls, 64 subjects with FXS without autism and 40 subjects with FXS and autism. Autism diagnosis was confirmed with ADOS, ADI-R and DSM IV criteria. Plasma was isolated and cytokine and chemokine production was assessed by Luminex multiplex analysis. RESULTS: Preliminary observations indicate significant differences in plasma protein levels of a number of cytokines, including IL-1alpha, and the chemokines; RANTES and IP-10, between the FXS group and the typical developing controls (p<0.01). In addition, significant differences were observed between the FXS group with autism and the FXS without autism for IL-6, eotaxin, MCP-1 (p<0.04). CONCLUSIONS: In this study, the first of its kind, we report a significantly altered cytokine profile in FXS. The characterization of an immunological profile in FXS with and without autism may help to elucidate if an abnormal immune response may play a role and help to identify mechanisms important in the etiology of autism both with and without FXS. Copyright 2010. Published by Elsevier Inc.
Authors: Walter E Kaufmann; Ranon Cortell; Alice S M Kau; Irena Bukelis; Elaine Tierney; Robert M Gray; Christiane Cox; George T Capone; Pia Stanard Journal: Am J Med Genet A Date: 2004-09-01 Impact factor: 2.802
Authors: Luke Heuer; Paul Ashwood; Joseph Schauer; Paula Goines; Paula Krakowiak; Irva Hertz-Picciotto; Robin Hansen; Lisa A Croen; Isaac N Pessah; Judy Van de Water Journal: Autism Res Date: 2008-10 Impact factor: 5.216
Authors: Susan W Harris; David Hessl; Beth Goodlin-Jones; Jessica Ferranti; Susan Bacalman; Ingrid Barbato; Flora Tassone; Paul J Hagerman; Herman Herman; Randi J Hagerman Journal: Am J Ment Retard Date: 2008-11
Authors: Paul Ashwood; Andrew Anthony; Alicia A Pellicer; Franco Torrente; John A Walker-Smith; Andrew J Wakefield Journal: J Clin Immunol Date: 2003-11 Impact factor: 8.317
Authors: David R Blair; Christopher S Lyttle; Jonathan M Mortensen; Charles F Bearden; Anders Boeck Jensen; Hossein Khiabanian; Rachel Melamed; Raul Rabadan; Elmer V Bernstam; Søren Brunak; Lars Juhl Jensen; Dan Nicolae; Nigam H Shah; Robert L Grossman; Nancy J Cox; Kevin P White; Andrey Rzhetsky Journal: Cell Date: 2013-09-26 Impact factor: 41.582
Authors: Paul Ashwood; Paula Krakowiak; Irva Hertz-Picciotto; Robin Hansen; Isaac Pessah; Judy Van de Water Journal: Brain Behav Immun Date: 2010-08-10 Impact factor: 7.217
Authors: Saleh A Bakheet; Mohammad Zeed Alzahrani; Mushtaq Ahmad Ansari; Ahmed Nadeem; Khairy M A Zoheir; Sabry M Attia; Laila Yousef Al-Ayadhi; Sheikh Fayaz Ahmad Journal: Mol Neurobiol Date: 2016-08-30 Impact factor: 5.590